Golimumab as First, Second or at Least Third Biologic Agent in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis -Post Hoc Analysis of a Non-Interventional Study in Germany
figureposted on 2020-04-09, 15:59 authored by Klaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, Matthias. H. Thomas
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.